16-3254293-T-C
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM2BP6
The NM_000243.3(MEFV):c.775A>G(p.Ile259Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000403 in 1,614,100 control chromosomes in the GnomAD database, with no homozygous occurrence. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000039 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000040 ( 0 hom. )
Consequence
MEFV
NM_000243.3 missense
NM_000243.3 missense
Scores
2
17
Clinical Significance
Conservation
PhyloP100: -0.202
Genes affected
MEFV (HGNC:6998): (MEFV innate immunity regulator, pyrin) This gene encodes a protein, also known as pyrin or marenostrin, that is an important modulator of innate immunity. Mutations in this gene are associated with Mediterranean fever, a hereditary periodic fever syndrome. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 1 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP6
Variant 16-3254293-T-C is Benign according to our data. Variant chr16-3254293-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 97545.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=8, not_provided=1, Benign=2}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MEFV | NM_000243.3 | c.775A>G | p.Ile259Val | missense_variant | 2/10 | ENST00000219596.6 | NP_000234.1 | |
MEFV | NM_001198536.2 | c.277+2018A>G | intron_variant | NP_001185465.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MEFV | ENST00000219596.6 | c.775A>G | p.Ile259Val | missense_variant | 2/10 | 1 | NM_000243.3 | ENSP00000219596.1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152206Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
6
AN:
152206
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251446Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135912
GnomAD3 exomes
AF:
AC:
8
AN:
251446
Hom.:
AF XY:
AC XY:
8
AN XY:
135912
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000404 AC: 59AN: 1461894Hom.: 0 Cov.: 32 AF XY: 0.0000413 AC XY: 30AN XY: 727248
GnomAD4 exome
AF:
AC:
59
AN:
1461894
Hom.:
Cov.:
32
AF XY:
AC XY:
30
AN XY:
727248
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152206Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74364
GnomAD4 genome
AF:
AC:
6
AN:
152206
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74364
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
3
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:9Benign:3Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Familial Mediterranean fever Uncertain:4Benign:1Other:1
Likely benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Feb 08, 2023 | - - |
not provided, no classification provided | literature only | Unité médicale des maladies autoinflammatoires, CHRU Montpellier | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 06, 2022 | This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 259 of the MEFV protein (p.Ile259Val). This variant is present in population databases (rs104895144, gnomAD 0.006%). This missense change has been observed in individual(s) with however, in one of these individuals, a homozygous pathogenic allele was also identified in MEFV, which suggests this c.775A>G variant was not the primary cause of disease and/or Mediterranean fever (PMID: 22614345, 24469716, 25626331, 31989427). ClinVar contains an entry for this variant (Variation ID: 97545). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 20, 2020 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 14, 2018 | The MEFV c.775A>G; p.Ile259Val variant (rs104895144), is reported in the literature in the heterozygous state in individuals affected with familial mediterranean fever (Ceylan 2012, Oztuzcu 2014, Tzifi 2014). This variant is reported in ClinVar (Variation ID: 97545), and is found in the general population with an overall allele frequency of 0.0032% (8/251,446 alleles) in the Genome Aggregation Database. The isoleucine at codon 259 is weakly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Due to limited information, the clinical significance of the p.Ile259Val variant is uncertain at this time. References: Ceylan GG et al. Frequency of alterations in the MEFV gene and clinical signs in familial Mediterranean fever in Central Anatolia, Turkey. Genet Mol Res. 2012 May 7;11(2):1185-94. Oztuzcu S et al. Screening of common and novel familial mediterranean fever mutations in south-east part of Turkey. Mol Biol Rep. 2014;41(4):2601-7. Tzifi F et al. Acute hepatitis in a child heterozygous for the I259V MEFV gene variant. Prague Med Rep. 2014;115(3-4):128-33. - |
Familial Mediterranean fever;C0085077:Acute febrile neutrophilic dermatosis;C1851347:Familial Mediterranean fever, autosomal dominant Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 12, 2024 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 22, 2016 | Variant summary: The variant c.775A>G (p.Ile259Val) affects a non-conserved nucleotide and results in replacement of Valine with an Isoleucine. Both amino acids are medium size and hydrophobic and therefore this substitution likely does not change the physico-chemical property of the protein. 5/5 in silico tools predict benign outcome for this change. The variant was found in the large and broad cohorts of the NHLBI-ES and ExAC projects at an allele frequency of 0.0025% which does not exceed the maximal expected allele frequency for a disease-causing MEFV variant (2.17%). However, the possibility that this variant may still represent as a rare polymorphism cannot be ruled out. There are a few patients with symptoms of FMF reported in the literature who carried the variant; however, most of these patient reports lack detailed clinical phenotypic data. Importantly, one patient with symptoms of FMF also carried p. M694V in homozygous state, indicating this variant may not be pathogenic or it acts as modifier of the pathogenic variant p.M694V. The variant p.M694V is known to be a highly penetrant pathogenic variant. Deletion of p.M694 has been shown to be causal for dominant FMF which also highlights the importance of p.M694 residue. There are no in vivo/vitro studies to describe the functional impact of the variant till date. Infevers database lists variant in one Turkish patient with a classification of VUS (unknown consequence) and HGMD lists variant with a classification of "Disease-Mutation". In summary, collective evidence suggests that this variant is unlikely to be pathogenic and it was classified as a VUS-possibly benign until more information becomes available. - |
Autoinflammatory syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Nov 30, 2021 | - - |
MEFV-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 02, 2023 | The MEFV c.775A>G variant is predicted to result in the amino acid substitution p.Ile259Val. This variant has been reported in five patients with familial Mediterranean fever (FMF), although segregation data was not presented in any of these cases and one patient was also homozygous for a different pathogenic variant (Ceylan et al. 2012. PubMed ID: 22614345; Oztuzcu et al. 2014. PubMed ID: 24469716; Tzifi et al. 2014. PubMed ID: 25626331; Balta et al. 2020. PubMed ID: 31989427). This variant was also reported in a patient with early coronary heart disease (Basar et al. 2014. PubMed ID: 24702757). This variant is reported in 0.0065% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-3304293-T-C). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Acute febrile neutrophilic dermatosis Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Feb 08, 2023 | - - |
Familial Mediterranean fever, autosomal dominant Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Feb 08, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T
M_CAP
Benign
T
MetaRNN
Uncertain
T
MetaSVM
Benign
T
MutationAssessor
Benign
N
PrimateAI
Benign
T
PROVEAN
Benign
N
REVEL
Uncertain
Sift
Benign
T
Sift4G
Benign
T
Polyphen
B
Vest4
MutPred
Gain of helix (P = 0.005);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at